JCA Reports & Regulatory Divergence

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: tovorafenib JCA report, mirvetuximab CDF, D-VRd reversal, and avacopan regulatory crisis. Let's get into it.

MarcusThe first JCA report on tovorafenib is out. It signals how joint assessments are handling rare disease evidence gaps. The report emphasizes surrogate endpoints and extrapolation, but HTA bodies remain skeptical of data quality. Transparency is improving, but reimbursement impact is still unclear.

SaraTransparency alone doesn't solve commercial risks. If HTA bodies use these reports to justify restrictive reimbursement, companies will deprioritize rare disease development. The precedent could stifle innovation where it's needed most.

MarcusThe alternative is no assessment at all. The JCA framework is pragmatic for unmet needs. Companies must accept the trade-offs.

SaraThat's a dangerous assumption. The process demands more robust evidence generation upfront, not just access. Otherwise, we're setting up for future reversals and market instability.

MarcusMoving to mirvetuximab soravtansine's interim CDF recommendation. It's a positive signal for ADCs, acknowledging novel mechanisms and unmet needs. The recommendation relies on progression-free survival from single-arm trials.

SaraBut single-arm trials with historical comparators? HTA bodies are demanding contemporary controls, especially for high-cost therapies. This interim recommendation might not hold in final appraisal, creating access uncertainty for ADC portfolios.

MarcusThe CDF is designed for this scenario. It enables patient access while generating real-world evidence. That's pragmatic innovation.

SaraPragmatic for patients, but commercially perilous. If final recommendations fail, it erodes trust in the pathway. Companies will hesitate to invest in ADCs without stronger evidence upfront.

MarcusNICE's reversal on D-VRd for multiple myeloma is significant. They now recommend it first-line based on MRD data. HTA bodies are adapting to surrogate endpoints when validated by clinical communities.

SaraMRD is a surrogate, not direct patient benefit. Cost-effectiveness models extrapolate from MRD to overall survival—that's speculative. This reversal risks normalizing surrogate endpoints without proven survival gains, driving unsustainable costs.

MarcusThe alternative is delaying access for years while overall survival data matures. Patients need options now. The reversal aligns with NICE's flexible threshold approach.

SaraFlexibility shouldn't compromise evidence rigor. Companies will exploit this for high-cost therapies, undermining value demonstration. The evidence strategy must prioritize hard endpoints.

MarcusAvacopan's cross-jurisdictional regulatory crisis highlights HEOR challenges. FDA approval for ANCA-associated vasculitis contrasts with EMA concerns, creating divergent evidence interpretations. HEOR teams must tailor dossiers for each region.

SaraThis fragmentation forces resource-intensive evidence strategies. Regulatory uncertainty fragments market access, complicating commercial planning. Companies need global harmonization, not regional battles.

MarcusHEOR must adapt to this reality. Novel therapies will face more divergence, requiring agile evidence generation.

SaraThe takeaway: HTA evolution creates commercial risks. Evidence strategies must address both evidence gaps and regulatory fragmentation.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.